dicyclopropylmethanethione | 38381-24-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代羰基化合物
• 英文名称: dicyclopropylmethanethione
• 英文别名: dicyclopropylthioketone；Dicyclopropylthioketon
• CAS: 38381-24-7
• 化学式: C₇H₁₀S
• 分子量: 126.222
• InChiKey: KFENTQGFOBLHNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  32.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  dicyclopropylmethanethione 在 臭氧 作用下， 以 乙醚 为溶剂， 以100%的产率得到双环丙基酮
  参考文献：
  名称：

  硫酮与羰基氧化物和3,3-二甲基-1,2-二环氧乙烷的反应。[3 + 2]环加成VS。氧原子转移

  摘要：

  在金刚烷-2-硫酮4a和双环[3.3.1]壬南-9-硫酮4b的存在下，乙烯基醚1a，b的臭氧分解在每种情况下均产生中等产率的相应硫代氧化物5a – c，同时将混合物进行臭氧分解乙烯基醚的1A - d和thiobenzophenone衍生物4F - ħ，得到相应的硫酮小号-oxides 8F - ħ在10-40％的产率分离出，用二苯甲酮一起7F - ħ。3,3-二甲基-1,2-二环氧乙烷，原位生成从丙酮的反应和“过硫酸氢钾”（2KHSO 5 - KHSO 4 -K 2 SO 4），转移氧原子的化合物4A，˚F，克，我提供硫酮小号-oxides 8A，˚F，克，我在29 –97％的收率。

  DOI：

  10.1039/p19910003043
• 作为产物：
  描述：

  双环丙基酮 在 劳森试剂 作用下， 以 甲苯 为溶剂， 生成 dicyclopropylmethanethione
  参考文献：
  名称：

  新的脯氨酰内肽酶抑制剂：氮杂双环[2.2.2]辛烷，氮杂双环[2.2.1]庚烷和全氢吲哚衍生物的体外和体内活性。

  摘要：

  通过取代1- [1-（4-（苯基苯基丁酰基）-L-脯氨酰基]吡咯烷酮的经典中心脯氨酸（SUAM 1221,3），已获得了一系列有效且选择性的α-酮杂环类型的脯氨酸肽肽酶（PEP）抑制剂。由非天然氨基酸PHI，ABO和ABH组成。这些含4-苯基丁酰基侧链的抑制剂表现出强大的体外抑制能力，IC50约为30 nM（化合物24和25）。通过用二环丙基部分取代末端苯环来调节侧链，得到具有增强的效力（IC 50在10和20nM之间）的衍生物30和32。此外，用（2-苯基环丙基）羰基实体取代直链的4-苯基丁酰基侧链，提供了有效的抑制剂，在大鼠皮层酶制剂上（化合物70）的IC50最终达到0.9 nM。环丙基环的构型必须为R，R，以便不仅在体外获得强PEP抑制，而且在体内具有良好的活性，例如抑制剂68，其ID50 ip和po分别为0.3和1 mg / kg ， 分别。最后，在使用东amine碱引起的失忆症的

  DOI：

  10.1021/jm950858c

文献信息

• Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
  申请人：NitroMed, Inc.

  公开号：US06297260B1

  公开（公告）日：2001-10-02

  The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

  本发明描述了新颖的硝化和/或亚硝化非甾体抗炎化合物，以及包含至少一种硝化和/或亚硝化非甾体抗炎化合物的新型组合物，还可以包含至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物。本发明还提供了治疗、预防和/或减轻炎症、疼痛和发热的方法；减少或逆转使用非甾体抗炎药物导致的胃肠道、肾脏和其他毒性反应；治疗和/或预防胃肠道疾病；治疗炎症性疾病状态和疾病；以及治疗和/或预防眼科疾病或疾病的方法。
• Thiocarbonyls into carbonyls: efficient conversion by clay-supported ferric nitrate
  作者：Stephane Chalais、André Cornelis、Pierre Laszlo、Arthur Mathy

  DOI：10.1016/s0040-4039(00)95088-3

  日期：1985.1

  A simple and inexpensive procedure is proposed for achieving the title transformation. The method works best with thiobenzophenones (60–100 % yields).

  提出了一种简单且廉价的过程来实现标题转换。该方法最适合于硫代二苯甲酮（60-100％的产率）。
• Nitric oxide donors, compositions and methods of use related applications
  申请人：——

  公开号：US20030203915A1

  公开（公告）日：2003-10-30

  The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

  该发明描述了新颖的一氧化氮供体和至少含有一个一氧化氮供体的新型组合物。该发明还提供了至少含有一个一氧化氮供体的新型组合物，以及可选地至少含有一个治疗剂。该发明的化合物和组合物也可以与基质结合。该发明还提供了治疗心血管疾病的方法，用于抑制血液暴露于医疗器械引起的血小板聚集和血小板粘附，用于治疗由于异常细胞增殖导致的病理状况；移植排斥、自身免疫、炎症、增殖、过度增殖、血管疾病；用于减少瘢痕组织或抑制伤口收缩，特别是通过给予一氧化氮供体的预防性和/或治疗性治疗以及至少一个治疗剂的组合来治疗再狭窄的方法。该发明还提供了治疗炎症、疼痛、发热、胃肠道疾病、呼吸道疾病和性功能障碍的方法。一氧化氮供体可以捐赠、转移或释放一氧化氮，并/或提高内源性内皮血管舒张因子的水平，并/或刺激内源性一氧化氮的合成和/或是一氧化氮合酶的底物，能够在生理条件下释放一氧化氮或间接地将一氧化氮传递或转移至靶向部位。治疗剂可以选择性地用至少一个NO和/或NO2基（即亚硝基化和/或亚硝化）替代。该发明还提供了至少含有一个一氧化氮供体和/或至少一个治疗剂的新型组合物和试剂盒。
• Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use
  申请人：——

  公开号：US20020016322A1

  公开（公告）日：2002-02-07

  The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

  本发明描述了新型的亚硝酸化和/或亚硝基化的非甾体抗炎化合物，以及包含至少一种亚硝酸化和/或亚硝基化的非甾体抗炎化合物的新型组合物，以及可选地含有至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物。本发明还提供了治疗、预防和/或减轻炎症、疼痛和发热的方法；减少或逆转由非甾体抗炎药物使用引起的胃肠道、肾脏和其他毒性；治疗和/或预防胃肠道疾病；治疗炎症性疾病和疾病状态；以及治疗和/或预防眼科疾病或疾病状态。
• Studies on organophosphorus compounds XX. syntheses of thioketones
  作者：B. S. Pedersen、S. Scheibye、N. H. Nilsson、S.-O. Lawesson

  DOI：10.1002/bscb.19780870310

  日期：——

  AbstractSubstituted benzophenones, 2‐benzoylthiophene, 3‐benzoylpyridine, dicyclopropyl ketone, and camphor are converted into the corresponding thioketones after reaction with the dimer of p‐methoxyphenylthionophosphine sulfide, 1. Except for the pyridine derivatives (2‐ and 4‐benzoylpyridines, respectively, gave no thioketones) very high yields are found. Under the same conditions dibenzylketone gave 1,3‐diphenylpropene‐2‐thiol and 1,9‐benzanthr‐10‐one yielded the dimer of 1,9‐benzanthr‐10‐thione. Aromatic thioketones are also obtained by reacting gem‐dichlorides with 2‐methyl‐2‐propane‐thiol in the presence of catalytic amounts of CF3COOH (or AlCl3). A mechanism is suggested based on kinetic measurements. 13C NMR data of the thiocarbonyls of all thioketones are recorded and a function describing the relation between the chemical shifts of CS and CO is found: δCS1.57 δCO=71.45

表征谱图